Sweet Enough? Takeda Raises, Adds Cash To Shire Offer
Takeda has further bumped up its offer for acquisition target Shire, raising the per share price and cash component, in what the Japanese firm says is a “compelling” proposal worth well over $60bn. Will it be fourth time lucky?
You may also be interested in...
Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.
Takeda further ups its offer for Shire to around £49 per share, which Shire’s board has said it is willing to recommend to shareholders, although any final deal remains subject to conditions and Takeda investors appear concerned over the size of the transaction.
Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.